Empagliflozin is beneficial for the health of patients with acute heart failure

Empagliflozin has demonstrated clinical benefit for patients hospitalized with acute heart failure, according to a study presented at the 2021 American Heart Association Scientific Sessions. These benefits included increased survival, a lower risk of readmission to hospital for heart failure, and an overall improvement in quality of life. .

“This is the first time that we have truly seen this type of drug work so effectively and safely in patients hospitalized with acute heart failure, regardless of their history of heart failure or their diabetes status,” said Adriaan Voors, MD, PhD, professor of cardiology. at the University Medical Center Groningen in the Netherlands, in a press release. “These findings may lead to earlier and more frequent treatment with empagliflozin, which may improve the lives of more people with heart failure.”

Empagliflozin, an SGLT2 inhibitor, was originally used to treat patients with type 2 diabetes. It has recently become an established therapy in patients with chronic heart failure, with the EMPULSE trial designed to determine if there is any benefit in people hospitalized with acute heart failure once their condition has stabilized.

The controlled, randomized, double-blind study included 530 adults with a mean age of 68 years, of which 66% were men. Participants were divided into 2 groups: 1 receiving a 90-day supply of empagliflozin 10 mg tablets and the other receiving a 90-day supply of a placebo pill. Patients were advised to take 1 tablet per day.

According to the researchers, people treated with empagliflozin were 36% more likely to experience clinical benefit, such as reduced all-cause mortality, fewer heart failure events, and improved symptoms. heart failure compared to those receiving placebo. These improvements were seen regardless of the type of heart failure or type 2 diabetes.

“Although there are several drugs available to improve clinical outcomes in patients with chronic heart failure, very few drugs have been shown to be beneficial for patients with new acute heart failure requiring hospitalization,” said Voors in the press release. “Our results indicate that empagliflozin may help improve outcomes for these patients without increasing serious side effects.”

REFERENCE

Adults with acute heart failure benefit from treatment with type 2 diabetes medicine [news release]. EurekAlert; November 15, 2021. Accessed November 16, 2021. https://www.eurekalert.org/news-releases/934869

Source link

About Jonathan J. Kramer

Check Also

Biden addresses nation a year after Jan 6 attack on Capitol – live updates

President Joe Biden has marked a year since the January 6 assault on the United …